Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Buti

Showing results (921-930 of 1,095) with videos related to

Pageof 110
Sort By:
Brazilian Journal of Microbiology : [Publication of the Brazilian Society for Microbiology]|July 29, 2022
Diagnosis and successful treatment of Brazillian porcupine poxvirus infection in a free-ranging hairy dwarf porcupine (Coendu spinosus)Juliana Mariotti Guerra, Pedro Enrique Navas-Suárez, Eduardo Ferreira-Machado, et al.
Journal of Hepatology|February 11, 2018
Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general populationGeorge V Papatheodoridis, Vana Sypsa, George Dalekos, et al.
The Lancet. Infectious Diseases|February 25, 2016
Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trialMichael Manns, Didier Samuel, Edward J Gane, et al.
The Journal of Infection|July 26, 2020
GEHEP 010 study: Prevalence and distribution of hepatitis B virus genotypes in Spain (2000-2016)Antonio Aguilera, Rocío Trastoy, Francisco Rodríguez-Frias, et al.
Future Oncology (London, England)|June 11, 2024
Analyses of tumor microenvironment in patients with advanced renal cell carcinoma receiving immunotherapy (Meet-URO 18 study)Fabio Catalano, Matteo Brunelli, Alessio Signori, et al.
Alimentary Pharmacology & Therapeutics|September 27, 2024
Eight-year efficacy and safety of tenofovir alafenamide for treatment of chronic hepatitis B virus infection: Final results from two randomised phase 3 trialsMaria Buti, Young-Suk Lim, Henry Lik Yuen Chan, et al.
JHEP Reports : Innovation in Hepatology|May 20, 2026
Progression to cirrhosis in chronic hepatitis D with mild-to-moderate fibrosis: insights from a multicenter European cohortSabela Lens, Habiba Kamal, Arno Furquim d'Almeida, et al.
Frontiers in Microbiology|April 20, 2026
Unveiling pathogens and contaminants: refining metagenomics for clinical diagnosticsMarta Ibañez-Lligoña, Sergi Colomer-Castell, Carolina Campos, et al.
ESMO Open|December 9, 2022
Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access ProgramS E Rebuzzi, A Signori, S Buti, et al.
Hepatology (Baltimore, Md.)|June 17, 2017
The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis BGeorge V Papatheodoridis, Ramazan Idilman, George N Dalekos, et al.
Pageof 110

Showing results (921-930 of 1,095) with videos related to

Sort By:
Pageof 110
Brazilian Journal of Microbiology : [Publication of the Brazilian Society for Microbiology]|July 29, 2022
Diagnosis and successful treatment of Brazillian porcupine poxvirus infection in a free-ranging hairy dwarf porcupine (Coendu spinosus)Juliana Mariotti Guerra, Pedro Enrique Navas-Suárez, Eduardo Ferreira-Machado, et al.
Journal of Hepatology|February 11, 2018
Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general populationGeorge V Papatheodoridis, Vana Sypsa, George Dalekos, et al.
The Lancet. Infectious Diseases|February 25, 2016
Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trialMichael Manns, Didier Samuel, Edward J Gane, et al.
The Journal of Infection|July 26, 2020
GEHEP 010 study: Prevalence and distribution of hepatitis B virus genotypes in Spain (2000-2016)Antonio Aguilera, Rocío Trastoy, Francisco Rodríguez-Frias, et al.
Future Oncology (London, England)|June 11, 2024
Analyses of tumor microenvironment in patients with advanced renal cell carcinoma receiving immunotherapy (Meet-URO 18 study)Fabio Catalano, Matteo Brunelli, Alessio Signori, et al.
Alimentary Pharmacology & Therapeutics|September 27, 2024
Eight-year efficacy and safety of tenofovir alafenamide for treatment of chronic hepatitis B virus infection: Final results from two randomised phase 3 trialsMaria Buti, Young-Suk Lim, Henry Lik Yuen Chan, et al.
JHEP Reports : Innovation in Hepatology|May 20, 2026
Progression to cirrhosis in chronic hepatitis D with mild-to-moderate fibrosis: insights from a multicenter European cohortSabela Lens, Habiba Kamal, Arno Furquim d'Almeida, et al.
Frontiers in Microbiology|April 20, 2026
Unveiling pathogens and contaminants: refining metagenomics for clinical diagnosticsMarta Ibañez-Lligoña, Sergi Colomer-Castell, Carolina Campos, et al.
ESMO Open|December 9, 2022
Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access ProgramS E Rebuzzi, A Signori, S Buti, et al.
Hepatology (Baltimore, Md.)|June 17, 2017
The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis BGeorge V Papatheodoridis, Ramazan Idilman, George N Dalekos, et al.
Pageof 110